Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?

Topics: Rheumatology • Vasculitis • ANCA Vasculitis • Journal Club ft. NEJM publications • Dermatology

ADVOCATE trial

Answer from: at Community Practice

Once Avacopan is available for clinical use in the treatment of patients with AAV, providers will need to carefully weigh risks and benefits of the medication while considering other factors including cost.The ADVOCATE trial used a novel glucocorticoid toxicity index that captures common GC-related ...

Comments

at Cleveland Clinic
Suspect as time goes by (and data stays +), it wil...

at Arthritis and Rheumatism Associates, P.C.
Excellent points. US rheum drug prices are driven ...

Related Questions